Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.78 |
| ▸ | AR | P10275 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.78 |
| ▸ | ESR1 | P03372 | 4/20 | 0.78 |
| ▸ | SHBG | P04278 | 4/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11858281 | 1.00 | PGR (0.78) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL11858793 | 0.92 | PGR (0.66) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL11862865 | 0.92 | PGR (0.66) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL25863862 | 0.91 | PGR (0.79) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL11868140 | 0.91 | PGR (0.79) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL25863926 | 0.91 | PGR (0.79) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL10930932 | 0.90 | PGR (0.78) | PGRLMNAARCYP3A4SLC6A4 | |
| SCHEMBL10929203 | 0.90 | PGR (0.78) | PGRLMNAARCYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL27597 | 0.88 | PGR (1.00) | PGRLMNAARCYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL21741985 | 0.88 | PGR (1.00) | PGRLMNAARCYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| US-20210244678-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2021-08-12 | — | — | US | claimed |
| EP-3651746-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | Hera Health Solutions Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| US-10406099-B2 | Bioerodible contraceptive implant and methods of use thereof | GESEA BIOSCIENCES, INC. (US) | 2019-09-10 | — | — | US | claimed |
| WO-2019014076-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20190008792-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2019-01-10 | — | — | US | claimed |
| US-20180303659-A1 | BIOERODIBLE CONTRACEPTIVE IMPLANT AND METHODS OF USE THEREOF | Gesea Biosciences Inc. (US) | 2018-10-25 | — | — | US | claimed |
| US-9980850-B2 | Bioerodible contraceptive implant and methods of use thereof | GESEA BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | claimed |
| WO-2018064544-A1 | BIOERODIBLE CONTRACEPTIVE IMPLANT AND METHODS OF USE THEREOF | Gesea Biosciences Inc. (US) | 2018-04-05 | — | — | WO | claimed |
| US-20180085248-A1 | BIOERODIBLE CONTRACEPTIVE IMPLANT AND METHODS OF USE THEREOF | Gesea Biosciences Inc. (US) | 2018-03-29 | — | — | US | claimed |
| US-20110144077-A1 | TREATMENT OF RETINAL DEGENERATION | UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2011-06-16 | — | — | US | claimed |
| EP-2320912-A1 | TREATMENT OF RETINAL DEGENERATION | University College Cork-National University of Ireland, Cork (IE) | 2011-05-18 | — | — | EP | claimed |
| WO-2010016042-A1 | TREATMENT OF RETINAL DEGENERATION | UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK (IE) | 2010-02-11 | — | — | WO | claimed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | disclosed |
| US-12274797-B2 | Bioerodible drug delivery implants | HERA HEALTH SOLUTIONS INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-12-24 | — | — | US | disclosed |
| US-4885117-A | Process for the preparation of (Z)-17α-halovinyl steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-05 | — | — | US | disclosed |
| US-4005078-A | Dithioketal derivatives of 13-polycarbonalkylgon-4-en-3-ones | Smith, Herchel (US) | 1977-01-25 | — | — | US | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | CD44, CSGALNACT1, ALG1 | PGR 756/4885LMNA 4323/4885AR 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.